Randomized Trial of Iron Supplementation to Prevent Anemia in Very-low-birth-weight Infants

This study has been completed.
Information provided by (Responsible Party):
Kathleen Kennedy, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier:
First received: October 14, 2010
Last updated: February 23, 2012
Last verified: February 2012

The purpose of this study is to determine if iron supplementation in addition to routine iron intake decreases the risk of developing anemia in preterm infants.

Condition Intervention Phase
Drug: Iron Supplement
Drug: control
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized Trial Comparing Iron Supplementation Versus Routine Iron Intake in Very Low Birth Weight (VLBW) Infants

Resource links provided by NLM:

Further study details as provided by The University of Texas Health Science Center, Houston:

Primary Outcome Measures:
  • Plasma hematocrit at 36 weeks postmenstrual age [ Time Frame: 36 weeks postmenstrual age ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: July 2010
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: iron supplementation
2 mg/kg/day of elemental iron as a multivitamin with iron solution
Drug: Iron Supplement
2 mg/kg/day elemental iron as multivitamin with iron solution
Sham Comparator: control
multivitamin solution without iron
Drug: control
multivitamin solution without iron


Ages Eligible for Study:   up to 8 Weeks
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. birth weight: < 1500 grams
  2. Tolerating iron fortified preterm formula or fortified breast milk at 120cc/kg/day by 8 weeks of age
  3. ≤32 weeks adjusted post-menstrual age at the time of enrollment

Exclusion Criteria:

  1. cyanotic heart disease
  2. bowel resection prior to enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01224236

United States, Texas
Children's Memorial Hermann Hospital
Houston, Texas, United States
Sponsors and Collaborators
The University of Texas Health Science Center, Houston
Principal Investigator: Kennedy Kathleen, MD The University of Texas Health Science Center, Houston
  More Information

No publications provided

Responsible Party: Kathleen Kennedy, Professor - Pediatrics, Neonatology, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier: NCT01224236     History of Changes
Other Study ID Numbers: RCT of Iron Supplementation
Study First Received: October 14, 2010
Last Updated: February 23, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Birth Weight
Body Weight
Signs and Symptoms
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Trace Elements

ClinicalTrials.gov processed this record on May 27, 2015